Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2022 06:00 ET | Source: Cerecin

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms

The authorization of the IND for Infantile Spasms (IS) is the third for tricaprilin, with other INDs open in Alzheimer’s disease and migraineA pilot study of CER-0001 in IS is ongoing in Australia and...
November 03, 2022 07:00 ET | Source: Cerecin

Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022

SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new...
October 31, 2022 07:00 ET | Source: Cerecin

Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study

Data from the RELIEF study, a pilot study assessing the safety and efficacy of the investigational compound CER-0001 in participants with migraine, showed a positive efficacy signal The outcome...
October 10, 2022 07:00 ET | Source: Cerecin

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical OfficerDr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development...
September 28, 2022 06:00 ET | Source: Cerecin

Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development

Series IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile...
December 14, 2021 07:00 ET | Source: Cerecin

Cerecin Announces Appointment of Milan Vinnola as General Counsel

DENVER and SINGAPORE, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the appointment of...
November 09, 2021 07:00 ET | Source: Cerecin

Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms

SINGAPORE and DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the enrollment of...
October 19, 2021 07:00 ET | Source: Cerecin

Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders

Prominent banks and institutional investors from South Korea follow an earlier cornerstone investment from Cerecin’s long-term partner, Nestlé.Proceeds will be used to fund product and pipeline...
February 04, 2021 06:00 ET | Source: Cerecin

Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls

Colorado USA, Melbourne Australia, and Singapore, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering ketogenic neurotherapeutics, today announced the...
December 17, 2020 07:40 ET | Source: Cerecin

Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)

Colorado, USA and Melbourne, Australia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on brain therapeutics, announced the enrollment of the first patient in its...